| Name | Title | Contact Details |
|---|---|---|
Vinay Bhupathy |
General Counsel | Profile |
In 2013, co-founders Philip Ross and Sophia Wang formed MycoWorks, a San Francisco-based biomaterials company dedicated to bringing new mycelium-grown materials to the world. MycoWorks` patented Fine Mycelium™ technology, an advanced manufacturing platform and breakthrough in materials science, engineers mycelium during growth to form proprietary, interlocking cellular structures for unparalleled beauty, handfeel, strength and durability. The company`s flagship material- Reishi™ - is a new category of material for the world`s best luxury brands.
Yield10 Bioscience is an agricultural bioscience company focusing on the development of disruptive technologies to produce step-change improvements in crop yield for food and feed crops to enhance global food security. Experts forecast that food production must be increased by over 70% in the next 35 years to feed the growing global population, which is expected to increase from 7 billion to more than 9.6 billion by 2050. Yield10 is focused on new agricultural biotechnology approaches to improve fundamental elements of plant metabolism through enhanced photosynthetic efficiency and directed carbon utilization. Yield10 is working to develop, validate and commercialize new traits and identify gene editing targets in several key crops including canola, soybean and corn. Yield10 was launched by Metabolix, Inc. in 2015 and is traded on Nasdaq (YTEN). Yield10 is headquartered in Woburn, MA and has an additional agricultural science facility with greenhouses in Saskatoon, Saskatchewan, Canada.
EpiVax Oncology is developing precision cancer immunotherapies based on mutanome-directed neo-epitopes, selected using proprietary and validated in silico predictive algorithms. Neo-epitopes are mutated and tumor specific epitopes, recognized as non-self, capable of generating highly potent specific T cell immunogenic responses against tumors, translating in improved clinical outcome. EpiVax Oncology is developing neo-epitope based therapeutic vaccines customized and specifically designed for each cancer patient, based on the genetic profiling (using next generation DNA sequencing) of each patient`s unique tumor and normal genome sequence (the mutanome). EpiVax Oncology`s ultimate purpose is to address major unmet medical needs inadequately addressed by other oncology and immuno-oncology treatments which are either only benefiting a very limited subset of patients, or prone to adverse events, or extremely costly and complex to manufacture. EpiVax Oncology`s ambition is to become a premier cancer precision medicine company, leveraging EpiVax`s world class excellence in computational-immunology, genomics and vaccine design, built over the last 20 years.
Kyowa Pharmaceutical is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Trovagene is a molecular diagnostics company providing precise, noninvasive urine and blood testing for detecting and monitoring oncogene mutations. By utilizing proprietary technology that analyzes circulating tumor DNA, Trovagene testing offers critical data that may help inform cancer treatment decisions, giving physicians and patients monitoring options beyond biopsy or imaging.